EGFR and lymphangioma: Of the 14 patients who received third-generation EGFR TKIs (i.e., osimertinib and zorifertinib/AZD3759) before developing LM, 12 continued to receive osimertinib, and two did not receive any EGFR TKIs treatment after LM diagnosis.